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TOP CITED PAPERS IN INTERNATIONAL PSYCHOGERIATRICS: 1. LONG-TERM USE OF
RIVASTIGMINE IN PATIENTS WITH DEMENTIA WITH LEWY BODIES: AN OPEN-LABEL TRIAL
Reflection
Eleven authors, 29 patients and an open-label
design would not generally be regarded as strong
predictors of a publication’s citation success, so
this one (Grace et al., 2001) probably needs some
explaining. I was advised early in my prospective
publishing career always to look for “a gap in the
market” and in 2001 this short paper probably filled
a significant gap in clinical knowledge. It was almost
a decade since the first reports had appeared about
dementia with Lewy bodies (DLB) being a relatively
common cause of dementia in older people, and
by 2001 the first iteration of the consensus criteria
for DLB diagnosis was starting to be widely used.
Clinicians were therefore becoming more confident
about recognizing DLB in their clinics, realized
that cholinesterase inhibitors (ChEIs) were often
useful in symptom control, and wanted to know
more about their effects in the longer term. This
short paper gave them some useful evidence to
support their practice. The lead author, Janet
Grace, who was working as my clinical lecturer,
had for a couple of years been following up a
group of DLB patients whom she had originally
entered in an earlier placebo controlled study
(McKeith et al., 2000) and was interested in
charting their progress with the ready help of U.K.
colleagues in Essex, Manchester, Southampton
and Nottingham. Although the 21 patients who
remained on treatment did show some evidence of
disease progression after two years, neither their
Mini-mental State Examination (MMSE) scores
nor their Neuropsychiatric Inventory (NPI) scores
were significantly worse than at baseline. And
reassuringly their parkinsonism had not worsened,
which was a common concern at that time.
Gratifying as it is for our paper to top the
International Psychogeriatrics citation list, it is also
a paradoxical indicator that not a great deal of
additional research on the treatment of DLB has
appeared since. We have continued to publish
open-label treatment studies suggesting that the
profile of side effects of ChEIs in DLB differs
from Alzheimer’s disease, particularly with respect
to autonomic dysfunction (Thomas et al., 2005).
Rapid deterioration on sudden withdrawal of
treatment may occur (Minett et al., 2003) and dose
escalation, if tolerated, can produce clinical benefits
in non-responders (Pakrasi et al., 2006). ChEIs are
widely given to DLB patients in most countries,
but such prescribing remains off-license and there
is still a dearth of information about their use in
this population. As the current generation of anti-
dementia drugs approach their patent expiry dates
it seems unlikely that pharmaceutical company
sponsorship will be forthcoming to support the trials
necessary for DLB to become a licensed indication.
Now is the time to start approaching other funding
sources to support such studies. And as new agents
for the treatment of dementia appear, we must
ensure that DLB has a prominent place in their
development programs.
IAN MCKEITH
Professor of Old Age Psychiatry and Clinical Director
Institute of Ageing and Health, Newcastle University.
Newcastle upon Tyne, U.K.
Email: I.G.McKeith@newcastle.ac.uk
Commentary
With 57 citations to the end of 2006, the paper
of Grace et al. (2001) on which Ian McKeith
was senior author was a clear winner by eight
citations from its nearest rival in a very impressive
issue of International Psychogeriatrics, which also
saw publication of the fifth most highly cited
paper (Manes et al. 2001) in our history (Ames,
2009). Perhaps one reason why all eight top
papers clustered in the years 2000–2002 is that the
journal only acquired an impact factor in 2002,
so that papers published in the years 1989–1999
were comparatively disadvantaged (although the
journal’s citations are known to have a relatively
long half-life), while those published in subsequent
years have not had so long a period of time in which
to accumulate citations. Nevertheless, it is no small
achievement for any paper to garner 57 citations
within four and a half years of publication (the 2006
citation index considered only papers published in
2005 and earlier).
5
6 Commentary
I think that a combination of reasons account
for the high citation rate of this concise and well-
written descriptive study. McKeith is right to note
its relatively unique character. In addition, dementia
with Lewy bodies (DLB) is very obviously an
important illness, not only correctly to diagnose
lest one poison the patient with neuroleptics due
to misdiagnosis, but also because there is so much
potential for the clinician to do good. Unlike the
modest benefits seen when Alzheimer’s disease
is treated with a cholinesterase inhibitor (ChEI),
DLB is perhaps the only neurodegenerative disease
routinely treated by psychiatrists in which some
(not all) patients exhibit a remarkable degree of
improvement when medicated. Those of us who
have seen such phenomena in our clinical practice
are keen to cite whatever published evidence is
available to confirm the veracity of our observations.
McKeith and colleagues deserve the thanks of
all people with DLB and Parkinson’s disease
dementia (PDD) for turning what used to be
established wisdom on its head and demonstrating
that cholinergic transmission does not need to
be blocked when Lewy bodies are present, but
enhanced. In the impressive body of work that has
emanated from Newcastle upon Tyne since DLB
was first described, later defined and subsequently
refined, the paper of Grace et al. (2001) occupies
a place out of proportion to the relatively small
number of patients it describes. The importance
of DLB and its treatment within the discipline of
psychogeriatrics is further emphasized by the fact
that the next in the “for debate” series of articles
to be published in this journal will deal with the
relationship between DLB and PDD, while the most
recent previous debate that we published dealt with
the evidence for the utility of ChEIs themselves
(Ames et al., 2008). Neatly, our most cited paper
links these two important and much discussed
subjects, and perhaps that as much as anything
else explains its remarkable and well-justified pre-
eminence.
DAVID AMES
Editor-in-Chief International Psychogeriatrics, Melbourne,
Australia
Email: ipaj-ed@unimelb.edu.au
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